MEDX Oncology East


Session 2: Achieving Precision Care in Gastrointestinal Cancers

Thursday, September 7     9:15am – 11:15am

Description

Treatment selection is largely dependent on the goals of therapy; however, sequencing of standard therapies with newly approved therapies as patients progress is a key factor in improving quality of care. The approval of new agents and advances in mutation analysis have supported the individualization of treatments and subsequent improvements in survival for patients with gastrointestinal cancer. As new agents are expected to enter the treatment paradigm in 2017, clinicians will require guidance on how to best integrate these agents and navigate reimbursement and quality requirements of new payment models.

Session Outline

Faculty will discuss 3 patient stories to highlight the factors that impact treatment decisions in GI cancers. The presentation will be interactive featuring the use of iPads throughout the session. The following cases will be discussed:

  • Case 1: Unresectable Metastatic Colorectal Cancer
    • Refining 1st-line and 2nd-line treatment options for RAS mutant and wild-type mCRC
    • Implications for MSI-H metastatic CRC
  • Case 2: Unresectable Hepatocellular Cancer
    • Systemic therapy
    • 2nd-line therapy for HCC
    • Novel agents in clinical trials
  • Case 3: Gastric Cancer
    • Prognosis based on molecular subtype
    • Personalizing chemotherapy regimens
    • Immunotherapy for GEJ cancers

Q&A Session and Presentation Roundup

CME Information

AMA PRA Category 1 Credits™

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ANCC

Elsevier is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the EOCME, Elsevier’s accredited Provider Unit, and Rockpointe Oncology. Elsevier designates this activity for 2.0 CNE credits.

ACPE

Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 2.0 hour (0.10 CEUs) of continuing education credit (UAN: xxx).

This is an application-based activity.

Faculty Information

Coming Soon